These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 8420141

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metabolic aspects of the behavior of MPTP and some analogues.
    Tipton KF, McCrodden JM, Sullivan JP.
    Adv Neurol; 1993; 60():186-93. PubMed ID: 8420134
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M.
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH, Kupsch A.
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [Abstract] [Full Text] [Related]

  • 6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
    Pérez V, Morón J, Pastó M, Unzeta M.
    Neurobiology (Bp); 2000 Oct; 8(3-4):231-6. PubMed ID: 11225513
    [Abstract] [Full Text] [Related]

  • 8. Clinical chemistry of monoamine oxidase.
    Glover V, Sandler M.
    Cell Biochem Funct; 1986 Apr; 4(2):89-97. PubMed ID: 3486724
    [No Abstract] [Full Text] [Related]

  • 9. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
    Chiueh CC, Miyake H, Peng MT.
    Adv Neurol; 1993 Apr; 60():251-8. PubMed ID: 8380519
    [No Abstract] [Full Text] [Related]

  • 10. [Experimental models, of Parkinson disease].
    Luquin MR.
    Rev Neurol; 1993 Apr; 31(1):60-6. PubMed ID: 10948587
    [Abstract] [Full Text] [Related]

  • 11. Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
    Poirier J, Thiffault C.
    Eur Neurol; 1993 Apr; 33 Suppl 1():38-43. PubMed ID: 8375431
    [Abstract] [Full Text] [Related]

  • 12. Parkinson's disease.
    Lieberman AN.
    Compr Ther; 1986 Mar; 12(3):25-9. PubMed ID: 3486090
    [No Abstract] [Full Text] [Related]

  • 13. MAO-B and Parkinson's disease.
    Sturman SG, Steventon GB, Waring RH, Williams AC.
    Mov Disord; 1990 Mar; 5(4):338-9. PubMed ID: 2259360
    [No Abstract] [Full Text] [Related]

  • 14. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
    Cohen G.
    Adv Neurol; 1987 Mar; 45():119-25. PubMed ID: 3030068
    [No Abstract] [Full Text] [Related]

  • 15. MAO-B inhibitors in Parkinson's disease.
    Olanow CW.
    Adv Neurol; 1993 Mar; 60():666-71. PubMed ID: 8420207
    [No Abstract] [Full Text] [Related]

  • 16. MPTP and aging. Studies in the C57BL/6 mouse.
    Irwin I, DeLanney LE, Langston JW.
    Adv Neurol; 1993 Mar; 60():197-206. PubMed ID: 8420136
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
    Rajeswari A, Sabesan M.
    Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
    [Abstract] [Full Text] [Related]

  • 18. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J.
    Vopr Med Khim; 1997 Apr; 43(6):482-93. PubMed ID: 9503565
    [Abstract] [Full Text] [Related]

  • 19. [Characteristics of the disordered regulation of monoamine oxidase activity in pathological states and the regulatory role of the monoamine oxidases].
    Gorkin VZ.
    Vestn Akad Med Nauk SSSR; 1986 Apr; (8):8-13. PubMed ID: 3532612
    [No Abstract] [Full Text] [Related]

  • 20. Future strategies for the treatment of Parkinson's disease.
    Fahn S.
    Adv Neurol; 1993 Apr; 60():636-40. PubMed ID: 8420202
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.